The Power of Two: Effective Management of Severe Refractory Psoriasis Through Combined TYK2 and IL-23 Inhibition. (2025). SKIN The Journal of Cutaneous Medicine, 9(5), 2669-2673. https://doi.org/10.25251/kj8rwg98